Impact Factor
3.58
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.83
555 total citations
h5-index
25
h5 depth signal
Cited share
80.4%
123 of 153
Total citations
555
Citation footprint
Metric signal
3.82
External metric anchor
Self-citation
1.3%
7 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
269
China
115
Italy
53
United Kingdom
49
France
33
Citing Fields of Research
Cardiology
535
Diabetes
105
Lipids
89
Pharmacology & Toxicology
37
Kidney Diseases
29
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,401
Articles tracked across the journal lifetime
Indexed publication set
153
123 cited publications
Last 12 months
58
4.8 publications/month
Open access share
24.1%
14 OA publications in the last year
Leading citing country
United States
269 citing publications
Leading citing field
Cardiology
535 citing publications
Latest tracked publication
21 September 2026
10 recent records available
Coverage & Indexing History
v1n1, 2001-
v1n1, 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Broad Categories
Cardiology
Drug Therapy
Vascular Diseases
MeSH Descriptors
Cardiology
Cardiovascular Agents
Cardiovascular Diseases
Heart Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s40256-026-00827-3
Open DOI
Temporal Trends and Predictors of P2Y12 Inhibitor Selection and Switching Following Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
Introduction Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard care after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). While ticagrelor provides potent ischemic protection, ble...
02
DOI 10.1007/s40256-026-00828-2
Open DOI
Beta-Blockers for the Treatment of Arrhythmias: Which Drug for Which Arrhythmia? A State-of-the-Art Narrative Review
03
DOI 10.1007/s40256-026-00829-1
Open DOI
SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy
Cardiovascular-kidney-metabolic syndrome describes a complex interplay between cardiovascular disease, chronic kidney disease, and metabolic disorders. Recent randomized controlled trials have demonstrated beneficial effects of SGLT2 inh...
04
DOI 10.1007/s40256-026-00825-5
Open DOI
Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies
Lipoprotein(a) [Lp(a)] is a genetically determined, low-density lipoprotein-like particle that has emerged as an important and independent contributor to atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Elevated...
05
DOI 10.1007/s40256-026-00824-6
Open DOI
Vutrisiran in Transthyretin Amyloidosis: A Narrative Review
This report describes vutrisiran (Amvuttra®), a novel double-stranded small interfering ribonucleic acid (siRNA)–N-acetylgalactosamine (GalNAc) conjugate. A narrative literature review was conducted using a secondary database, PubMed, fr...
06
07
DOI 10.1007/s40256-026-00823-7
Open DOI
Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility
08
DOI 10.1007/s40256-026-00811-x
Open DOI
Evaluating the Impact of Stair Climbing on Cardiovascular Risk Reduction: A Systematic Review and Meta-analysis
09
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.